Why India needs a smarter healthcare margin policy

The current Maximum Retail Price (MRP) regime in healthcare often fails its primary purpose of consumer protection, instead acting as a default, inflated charge due to captive patient demand during emergencies. The National Pharmaceutical Pricing Authority (NPPA) has attempted to address this through trade-margin rationalisation (capping the profit margin allowed to intermediaries), as seen with 42 non-scheduled cancer medicines in 2019. However, the author argues for a more nuanced approach through an independent Healthcare Pricing and Value Panel. This panel would evaluate products based on clinical benefit, research risk, and disease burden, moving away from a one-size-fits-all margin cap. This aligns with the need for evidence-based policymaking, building upon the framework of Health Technology Assessment to ensure public funds and patient out-of-pocket expenditure translate to actual clinical value.

The economic critique centres on the lack of price transparency and the misallocation of profit margins within the healthcare supply chain. Currently, routine, high-volume consumables often carry exorbitant markups (e.g., a ₹11 product billed at ₹325) where the margin does not reflect the actual cost of stocking, handling, or sterility maintenance. The author advocates for a differential profit strategy. Routine items should have modest, transparent margins informed by bulk procurement prices. Conversely, a premium pricing model should be reserved for organizations taking substantial scientific risks to develop novel therapies, particularly for rare or neglected diseases. This approach incentivizes genuine innovation (developing new, effective treatments) rather than mere profiteering (exploiting a vulnerable market). The key economic challenge for regulators is to separate manufacturer profits from intermediary trade margins to ensure policies intended to reward research don't just enrich distributors.

The debate touches upon the core ethical conflict in healthcare: balancing corporate profitability with the fundamental right to health (implied under Article 21 of the Constitution). While acknowledging that companies require a return on investment to fund research, the current system allows for exploitative pricing practices where patients have no choice or bargaining power. The proposed solution emphasizes distributive justice by linking higher returns to demonstrable societal impact, such as preventing complications or providing reliable supply to underserved areas. Furthermore, the call for specific, measurable commitments to differential pricing for vulnerable patients highlights the ethical obligation of the pharmaceutical industry beyond token patient-assistance programs. Transparency in itemized billing and the disclosure of conflicts of interest by pricing panel members are crucial steps toward establishing probity in healthcare commerce.